Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05287451 · ClinicalTrials.gov registry record · NA
Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study
A NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 9
- Study locations
NCT05287451 is a NA study of Ovarian Cancer and Fallopian Tube Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The trial reports 9 study locations across 7 states.
The verdict
NCT05287451, a NA study of Ovarian Cancer and Fallopian Tube Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
Conditions Studied
Interventions
- OTHER RIsk-Reducing Salpingectomy (RRS)
- OTHER Risk-Reducing Oophorectomy-RRO
- OTHER Risk-Reducing Salpingo-Oophorectomy-RRSO
Study Locations (9)
New York
- Mount Sinai Health System - New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- Lyndon Baines Johnson General - Houston
- M D Anderson Cancer Center - Houston
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- WU St Louis - St Louis
Pennsylvania
- University of Pennsylvania - Philadelphia
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2026-12-26 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05287451
The ClinicalTrials.gov registry entry for NCT05287451 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (86% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 3 interventions - of which RIsk-Reducing Salpingectomy (RRS) is the first listed.
NCT05287451 reports 9 study locations spanning 7 distinct geographic areas - top geographies include New York, Texas, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05287451 about?
NCT05287451 is a clinical study titled "Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study". This is a prospective preference study that will evaluate non-inferiority of the innovative treatment (RRS with delayed RRO) as compared to the standard treatment (RRSO) with respect to high grade serous (ovarian) cancer incidence
What is the current status of trial NCT05287451?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2022-05-10. Estimated completion is 2026-12-26.
What conditions does trial NCT05287451 study?
This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer.
What interventions are being tested in trial NCT05287451?
The interventions under investigation include: RIsk-Reducing Salpingectomy (RRS) (OTHER), Risk-Reducing Oophorectomy-RRO (OTHER), Risk-Reducing Salpingo-Oophorectomy-RRSO (OTHER).
Who is sponsoring clinical trial NCT05287451?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05287451 being conducted?
This trial has 9 study locations across Massachusetts, Minnesota, Missouri, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
RECRUITING · NA
-
Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
RECRUITING · NA
-
REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP Inhibitors
RECRUITING · NA
-
Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.